| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |